Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Harrow, Inc. before investing.

In this article, we go over a few key elements for understanding Harrow, Inc.’s stock price such as:

• Harrow, Inc.’s current stock price and volume
• Why Harrow, Inc.’s stock price changed recently
• Upgrades and downgrades for HROW from analysts
• HROW’s stock price momentum as measured by its relative strength

About Harrow, Inc. (HROW)

Before we jump into Harrow, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Want to learn more about Harrow, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Harrow, Inc..

Harrow, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Harrow, Inc.’s stock price was $38.770.

Harrow, Inc. is down 0.44% from its previous closing price of $38.940.

During the last market session, Harrow, Inc.’s stock traded between $37.180 and $39.010. Currently, there are approximately 37.23 million shares outstanding for Harrow, Inc..

Harrow, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Harrow, Inc. Stock Price History

Harrow, Inc.’s (HROW) price is currently down 8.71% so far this month.

During the month of July, Harrow, Inc.’s stock price has reached a high of $47.500 and a low of $36.250.

Over the last year, Harrow, Inc. has hit prices as high as $54.850 and as low as $28.540. Year to date, Harrow, Inc.’s stock is down 20.88%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Harrow, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Harrow, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Harrow, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Harrow, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Harrow, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Harrow, Inc. (HROW) by visiting AAII Stock Evaluator.

Relative Price Strength of Harrow, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Harrow, Inc. has a weighted four-quarter relative price strength of -0.82%, which translates to a Momentum Score of 50 and is considered to be Average.

Want to learn more about how Harrow, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Harrow, Inc. Stock Price: Bottom Line

As of July 31, 2026, Harrow, Inc.’s stock price is $38.770, which is down 0.44% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Harrow, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.